Drugs / Activated CIK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03146637 | May 2017 → Jan 2021 | liver cancer | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT03524261 Comparator | May 2019 → Apr 2020 | breast cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03509298 Comparator | Apr 2018 → May 2020 | digestive system carcinoma | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03540199 Comparator | Apr 2018 → May 2020 | kidney cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03554395 Comparator | Apr 2018 → May 2020 | gastric cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03501056 Comparator | Mar 2018 → May 2020 | lung cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03484962 Comparator | Mar 2018 → May 2020 | liver cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Activated CIK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03524261 ↗ |
| Modality | Cell therapy | “CIK cells were activated by bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3” NCT03146637 ↗ |